Planning your early development journey?
Australia and New Zealand offer an attractive environment for early-stage pharmaceutical and biotechnology development, but successfully progressing from preclinical research to first-in-human studies requires the right analytical strategy and expertise.
In this expert Q&A, discover practical insights into:
- The opportunities driving early drug development in Australia and New Zealand
- Key analytical considerations when progressing from preclinical development to Phase I
- What to look for when selecting an analytical testing partner
- How specialist expertise can help reduce development risk and maintain momentum
Complete the form to download your complimentary Q&A